NCT07412262

A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Guangdong Association of Clinical Trials · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary immune resistance and high YAP protein expression.

Detailed description

Not provided

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Chidamide in combination with Ivonescimab	Chidamide 20mg/dose orally BIW; Ivonescimab 20mg/kg intravenously (IV) Q3W

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-03-31
• Completion: 2029-03-31
• First posted: 2026-02-17
• Last updated: 2026-02-17

Locations

2 sites across 1 country: China